Oncology expert Paul Rennert gives an update on Aleta Biotherapeutics and previews some targets at #ASCO24

Paul Rennert talks about the first four patients who have been dosed in Aleta's clinical trial, as well as previewing targets such as Claudin 18.2 and BCMA at ASCO.